195 related articles for article (PubMed ID: 32143456)
1. Conventional and Unconventional Therapeutic Strategies for Sialidosis Type I.
Mosca R; van de Vlekkert D; Campos Y; Fremuth LE; Cadaoas J; Koppaka V; Kakkis E; Tifft C; Toro C; Allievi S; Gellera C; Canafoglia L; Visser G; Annunziata I; d'Azzo A
J Clin Med; 2020 Mar; 9(3):. PubMed ID: 32143456
[TBL] [Abstract][Full Text] [Related]
2. AAV-mediated gene therapy for sialidosis.
van de Vlekkert D; Hu H; Weesner JA; Fremuth LE; Brown SA; Lu M; Gomero E; Campos Y; Sheppard H; d'Azzo A
Mol Ther; 2024 May; ():. PubMed ID: 38796704
[TBL] [Abstract][Full Text] [Related]
3. Pathogenesis, Emerging therapeutic targets and Treatment in Sialidosis.
d'Azzo A; Machado E; Annunziata I
Expert Opin Orphan Drugs; 2015; 3(5):491-504. PubMed ID: 26949572
[TBL] [Abstract][Full Text] [Related]
4. Chaperone-mediated gene therapy with recombinant AAV-PPCA in a new mouse model of type I sialidosis.
Bonten EJ; Yogalingam G; Hu H; Gomero E; van de Vlekkert D; d'Azzo A
Biochim Biophys Acta; 2013 Oct; 1832(10):1784-92. PubMed ID: 23770387
[TBL] [Abstract][Full Text] [Related]
5. AAV-mediated gene therapy for Sialidosis.
van de Vlekkert D; Hu H; Fremuth LE; Brown SA; Weesner JA; Gomero E; Campos Y; d'Azzo A
bioRxiv; 2023 Nov; ():. PubMed ID: 38014061
[TBL] [Abstract][Full Text] [Related]
6. Elimination of abnormal sialylglycoproteins in fibroblasts with sialidosis and galactosialidosis by normal gene transfer and enzyme replacement.
Oheda Y; Kotani M; Murata M; Sakuraba H; Kadota Y; Tatano Y; Kuwahara J; Itoh K
Glycobiology; 2006 Apr; 16(4):271-80. PubMed ID: 16361247
[TBL] [Abstract][Full Text] [Related]
7. Short-term, high dose enzyme replacement therapy in sialidosis mice.
Wang D; Bonten EJ; Yogalingam G; Mann L; d'Azzo A
Mol Genet Metab; 2005 Jul; 85(3):181-9. PubMed ID: 15979029
[TBL] [Abstract][Full Text] [Related]
8. Intermittent enzyme replacement therapy with recombinant human β-galactosidase prevents neuraminidase 1 deficiency.
Luu AR; Wong C; Agrawal V; Wise N; Handyside B; Lo MJ; Pacheco G; Felix JB; Giaramita A; d'Azzo A; Vincelette J; Bullens S; Bunting S; Christianson TM; Hague CM; LeBowitz JH; Yogalingam G
J Biol Chem; 2020 Sep; 295(39):13556-13569. PubMed ID: 32727849
[TBL] [Abstract][Full Text] [Related]
9. Gene therapy corrects the neurological deficits of mice with sialidosis.
Hwu WL; Chang K; Liu YH; Wang HC; Lee NC; Chien YH
Gene Ther; 2024 May; 31(5-6):263-272. PubMed ID: 38321198
[TBL] [Abstract][Full Text] [Related]
10. Neu4, a novel human lysosomal lumen sialidase, confers normal phenotype to sialidosis and galactosialidosis cells.
Seyrantepe V; Landry K; Trudel S; Hassan JA; Morales CR; Pshezhetsky AV
J Biol Chem; 2004 Aug; 279(35):37021-9. PubMed ID: 15213228
[TBL] [Abstract][Full Text] [Related]
11. Modeling Sialidosis with Neural Precursor Cells Derived from Patient-Derived Induced Pluripotent Stem Cells.
Seol B; Kim YD; Cho YS
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922276
[TBL] [Abstract][Full Text] [Related]
12. Molecular pathology of NEU1 gene in sialidosis.
Seyrantepe V; Poupetova H; Froissart R; Zabot MT; Maire I; Pshezhetsky AV
Hum Mutat; 2003 Nov; 22(5):343-52. PubMed ID: 14517945
[TBL] [Abstract][Full Text] [Related]
13. Protective protein/cathepsin A rescues N-glycosylation defects in neuraminidase-1.
Wang D; Zaitsev S; Taylor G; d'Azzo A; Bonten E
Biochim Biophys Acta; 2009 Apr; 1790(4):275-82. PubMed ID: 19714866
[TBL] [Abstract][Full Text] [Related]
14. In silico identification of new putative pathogenic variants in the NEU1 sialidase gene affecting enzyme function and subcellular localization.
Bonardi D; Ravasio V; Borsani G; d'Azzo A; Bresciani R; Monti E; Giacopuzzi E
PLoS One; 2014; 9(8):e104229. PubMed ID: 25153125
[TBL] [Abstract][Full Text] [Related]
15. Lysosomal sialidase NEU1, its intracellular properties, deficiency, and use as a therapeutic agent.
Itoh K; Tsukimoto J
Glycoconj J; 2023 Dec; 40(6):611-619. PubMed ID: 38147151
[TBL] [Abstract][Full Text] [Related]
16. Type 1 sialidosis presenting with ataxia, seizures and myoclonus with no visual involvement.
Mohammad AN; Bruno KA; Hines S; Atwal PS
Mol Genet Metab Rep; 2018 Jun; 15():11-14. PubMed ID: 30023283
[TBL] [Abstract][Full Text] [Related]
17. Heterodimerization of the sialidase NEU1 with the chaperone protective protein/cathepsin A prevents its premature oligomerization.
Bonten EJ; Campos Y; Zaitsev V; Nourse A; Waddell B; Lewis W; Taylor G; d'Azzo A
J Biol Chem; 2009 Oct; 284(41):28430-28441. PubMed ID: 19666471
[TBL] [Abstract][Full Text] [Related]
18. Biochemical and molecular characterization of novel mutations in GLB1 and NEU1 in patient cells with lysosomal storage disorders.
Kwak JE; Son MY; Son YS; Son MJ; Cho YS
Biochem Biophys Res Commun; 2015 Feb; 457(4):554-60. PubMed ID: 25600812
[TBL] [Abstract][Full Text] [Related]
19. Sialidosis: A Review of Morphology and Molecular Biology of a Rare Pediatric Disorder.
Khan A; Sergi C
Diagnostics (Basel); 2018 Apr; 8(2):. PubMed ID: 29693572
[TBL] [Abstract][Full Text] [Related]
20. Type I sialidosis, a normosomatic lysosomal disease, in the differential diagnosis of late-onset ataxia and myoclonus: An overview.
Caciotti A; Melani F; Tonin R; Cellai L; Catarzi S; Procopio E; Chilleri C; Mavridou I; Michelakakis H; Fioravanti A; d'Azzo A; Guerrini R; Morrone A
Mol Genet Metab; 2020 Feb; 129(2):47-58. PubMed ID: 31711734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
